Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors

NCT01121562 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01121562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01121562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
November 30, 2013
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumors